5-hydroxytryptophan has been researched along with Cardiac Hypertrophy in 3 studies
5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.
5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These results suggest that chronic administration of L-5-HTP provides significant protection against the development of DOCA-induced hypertension, polydipsia, polyuria, and cardiac hypertrophy in rats." | 5.27 | Chronic treatment with L-5-hydroxytryptophan prevents the development of DOCA-salt-induced hypertension in rats. ( Fregly, MJ; Lockley, OE; Sumners, C, 1987) |
| " These results suggest that chronic administration of L-5-HTP was effective in reducing the elevated blood pressure in the DS model." | 1.28 | Reduction in the elevated blood pressure of Dahl salt-sensitive rats treated chronically with L-5-hydroxytryptophan. ( Baron, A; Fregly, MJ; Riesselmann, A, 1991) |
| "Cardiac hypertrophy was associated with Dahl salt-induced hypertension." | 1.28 | Reduction in the elevated blood pressure of Dahl salt-sensitive rats treated chronically with L-5-hydroxytryptophan. ( Baron, A; Fregly, MJ; Riesselmann, A, 1991) |
| " These results suggest that chronic administration of L-5-HTP provides significant protection against the development of DOCA-induced hypertension, polydipsia, polyuria, and cardiac hypertrophy in rats." | 1.27 | Chronic treatment with L-5-hydroxytryptophan prevents the development of DOCA-salt-induced hypertension in rats. ( Fregly, MJ; Lockley, OE; Sumners, C, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baron, A | 1 |
| Riesselmann, A | 1 |
| Fregly, MJ | 2 |
| Lockley, OE | 1 |
| Sumners, C | 1 |
| O'Steen, WK | 1 |
| Hall, CE | 1 |
| Hall, OS | 1 |
3 other studies available for 5-hydroxytryptophan and Cardiac Hypertrophy
| Article | Year |
|---|---|
Reduction in the elevated blood pressure of Dahl salt-sensitive rats treated chronically with L-5-hydroxytryptophan.
Topics: 5-Hydroxytryptophan; Animals; Blood Pressure; Body Weight; Cardiomegaly; Desoxycorticosterone; Femal | 1991 |
Chronic treatment with L-5-hydroxytryptophan prevents the development of DOCA-salt-induced hypertension in rats.
Topics: 5-Hydroxytryptophan; Administration, Cutaneous; Angiotensin II; Animals; Cardiomegaly; Catecholamine | 1987 |
Hormone influenced hypertension in the male rat. Effect of hydrochlorothiazide.
Topics: 5-Hydroxytryptophan; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Ce | 1969 |